Takara Bio Inc
TSE:4974
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
941
1 276
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Takara Bio Inc
Takara Bio Inc
Total Liabilities & Equity
Takara Bio Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Takara Bio Inc
TSE:4974
|
Total Liabilities & Equity
¥121.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
GNI Group Ltd
TSE:2160
|
Total Liabilities & Equity
¥69B
|
CAGR 3-Years
34%
|
CAGR 5-Years
29%
|
CAGR 10-Years
27%
|
|
|
PeptiDream Inc
TSE:4587
|
Total Liabilities & Equity
¥93.4B
|
CAGR 3-Years
50%
|
CAGR 5-Years
38%
|
CAGR 10-Years
32%
|
|
|
Pharma Foods International Co Ltd
TSE:2929
|
Total Liabilities & Equity
¥36.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
33%
|
CAGR 10-Years
25%
|
|
|
S
|
StemRIM Inc
TSE:4599
|
Total Liabilities & Equity
¥9.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
C
|
Cuorips Inc
TSE:4894
|
Total Liabilities & Equity
¥6.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Takara Bio Inc
Glance View
Takara Bio, Inc. engages in development and marketing of genetic engineering technologies. The company is headquartered in Kusatsu-Shi, Shiga-Ken and currently employs 1,539 full-time employees. The company went IPO on 2004-12-07. The firm operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
See Also
What is Takara Bio Inc's Total Liabilities & Equity?
Total Liabilities & Equity
121.8B
JPY
Based on the financial report for Jun 30, 2024, Takara Bio Inc's Total Liabilities & Equity amounts to 121.8B JPY.
What is Takara Bio Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
7%
Over the last year, the Total Liabilities & Equity growth was 1%. The average annual Total Liabilities & Equity growth rates for Takara Bio Inc have been 7% over the past three years , 11% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet
